Target intelligence / Profile preview

Trans-activation response element (TAR)

Target
TAR
Molecular classification
Regulatory non-coding RNA element, Viral RNA regulatory sequence, Other (not protein, receptor, or enzyme)
01

Overview

The trans-activation response element (TAR) is a structured RNA hairpin located at the 5′ end of all nascent HIV transcripts, critical for the recruitment of the viral Tat protein. Upon Tat binding, P-TEFb is recruited, leading to phosphorylation of RNA polymerase II and transition from transcriptional pausing to processive elongation, which is absolutely essential for HIV replication[3][4][9]. The TAR–Tat–P-TEFb axis is a central regulator of the HIV lifecycle and a unique drug target, as disruption prevents viral gene expression and replication. While the TAR element itself is not a conventional receptor, enzyme, or protein target, it does serve as the necessary substrate for Tat-directed transactivation and is being explored as an antiviral therapeutic target in research, primarily to disrupt the Tat–TAR–P-TEFb interaction[2][4][9][10]. Structurally, TAR forms a stem-loop motif required for complex assembly, and its sequence and conformation can influence susceptibility to inhibitors and viral fitness[3][6][7].

Other names
TAR elementHIV TARTrans-activation response (TAR) element
02

Mechanism of action

For experimental drugs: Blockade or disruption of Tat–TAR RNA binding, inhibiting HIV transcriptional activation and viral replication

03

Biological functions

Essential for Tat-mediated transactivation of the HIV long terminal repeat (LTR) promoterFacilitates efficient transcriptional elongation by recruiting positive transcription elongation factor b (P-TEFb; contains cyclin T and CDK9)Biogenesis of viral and cellular microRNAs
04

Disease associations

Infection (HIV/AIDS)Indirectly linked to cancer via viral oncogenesis when similar mechanisms are hijacked by other viruses
05

Safety considerations

Targeting the TAR element directly poses risks of off-target effects, potential impact on host RNA structures, and challenges of RNA drug deliveryHIV may mutate in the TAR region, producing drug resistance or loss of efficacy
06

Interacting drugs

None in routine clinical use; however, there is experimental development of Tat–TAR interaction inhibitors as antiviral approaches

1 more in the full profile.

07

Biomarkers

Presence of TAR element RNA or Tat–TAR complex in cells may serve as markers for active HIV transcription

Beyond the preview

Go deeper on Trans-activation response element (TAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trans-activation response element (TAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call